Concepts (96)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Antimicrobial Stewardship | 3 | 2018 | 84 | 1.680 |
Why?
|
| Education, Pharmacy | 2 | 2023 | 50 | 1.570 |
Why?
|
| Students, Pharmacy | 2 | 2023 | 54 | 1.550 |
Why?
|
| Bacteria | 3 | 2021 | 611 | 1.080 |
Why?
|
| Microbial Sensitivity Tests | 8 | 2022 | 994 | 1.060 |
Why?
|
| Bacterial Infections | 2 | 2018 | 479 | 0.980 |
Why?
|
| Peer Review | 3 | 2018 | 80 | 0.890 |
Why?
|
| beta-Lactamase Inhibitors | 2 | 2022 | 52 | 0.790 |
Why?
|
| Lactams | 1 | 2021 | 24 | 0.770 |
Why?
|
| Communicable Diseases | 3 | 2018 | 193 | 0.760 |
Why?
|
| Absenteeism | 1 | 2020 | 24 | 0.750 |
Why?
|
| Anti-Bacterial Agents | 7 | 2022 | 2992 | 0.730 |
Why?
|
| Anti-Infective Agents | 3 | 2018 | 446 | 0.690 |
Why?
|
| Models, Psychological | 1 | 2020 | 170 | 0.680 |
Why?
|
| Periodicals as Topic | 3 | 2018 | 338 | 0.670 |
Why?
|
| Hospitals | 2 | 2019 | 485 | 0.660 |
Why?
|
| Clostridium Infections | 2 | 2019 | 252 | 0.660 |
Why?
|
| Ceftriaxone | 1 | 2018 | 67 | 0.640 |
Why?
|
| Teaching | 1 | 2020 | 243 | 0.630 |
Why?
|
| Bacterial Toxins | 1 | 2019 | 228 | 0.630 |
Why?
|
| Peritonitis | 1 | 2018 | 89 | 0.620 |
Why?
|
| Gram-Positive Bacteria | 1 | 2018 | 66 | 0.620 |
Why?
|
| Echinocandins | 1 | 2018 | 132 | 0.590 |
Why?
|
| Gram-Positive Bacterial Infections | 1 | 2018 | 157 | 0.580 |
Why?
|
| Drug Resistance, Multiple, Bacterial | 1 | 2018 | 202 | 0.580 |
Why?
|
| Enoxaparin | 1 | 2016 | 66 | 0.550 |
Why?
|
| Cross Infection | 1 | 2019 | 544 | 0.500 |
Why?
|
| Attitude of Health Personnel | 1 | 2020 | 918 | 0.460 |
Why?
|
| Bacteremia | 1 | 2018 | 689 | 0.430 |
Why?
|
| Health Knowledge, Attitudes, Practice | 1 | 2020 | 1209 | 0.420 |
Why?
|
| Lung Transplantation | 1 | 2016 | 359 | 0.410 |
Why?
|
| Antifungal Agents | 1 | 2018 | 834 | 0.410 |
Why?
|
| Hemorrhage | 1 | 2016 | 712 | 0.400 |
Why?
|
| Liver Cirrhosis | 1 | 2018 | 941 | 0.400 |
Why?
|
| Ceftazidime | 2 | 2022 | 57 | 0.400 |
Why?
|
| beta-Lactamases | 4 | 2022 | 179 | 0.390 |
Why?
|
| Klebsiella pneumoniae | 3 | 2022 | 98 | 0.380 |
Why?
|
| Anticoagulants | 1 | 2016 | 787 | 0.370 |
Why?
|
| Klebsiella Infections | 2 | 2022 | 64 | 0.360 |
Why?
|
| Tertiary Care Centers | 3 | 2018 | 403 | 0.310 |
Why?
|
| Drug Resistance, Bacterial | 2 | 2018 | 418 | 0.250 |
Why?
|
| Feedback | 1 | 2023 | 198 | 0.210 |
Why?
|
| Prevalence | 3 | 2018 | 3260 | 0.210 |
Why?
|
| Societies, Pharmaceutical | 2 | 2017 | 14 | 0.190 |
Why?
|
| Behavior Control | 1 | 2020 | 13 | 0.190 |
Why?
|
| Educational Measurement | 1 | 2023 | 362 | 0.190 |
Why?
|
| Pseudomonas Infections | 1 | 2021 | 156 | 0.190 |
Why?
|
| Bangladesh | 1 | 2019 | 24 | 0.180 |
Why?
|
| Public Health Surveillance | 1 | 2019 | 63 | 0.170 |
Why?
|
| Ribotyping | 1 | 2019 | 48 | 0.170 |
Why?
|
| Cystic Fibrosis | 1 | 2021 | 264 | 0.170 |
Why?
|
| Bacterial Proteins | 3 | 2022 | 1029 | 0.170 |
Why?
|
| Molecular Epidemiology | 1 | 2019 | 246 | 0.160 |
Why?
|
| Clinical Audit | 1 | 2018 | 11 | 0.160 |
Why?
|
| Choice Behavior | 1 | 2020 | 226 | 0.160 |
Why?
|
| Social Behavior | 1 | 2020 | 306 | 0.160 |
Why?
|
| Candida glabrata | 1 | 2018 | 45 | 0.160 |
Why?
|
| Curriculum | 1 | 2023 | 860 | 0.150 |
Why?
|
| Motivation | 1 | 2020 | 499 | 0.150 |
Why?
|
| Humans | 16 | 2023 | 261506 | 0.150 |
Why?
|
| Factor Xa | 1 | 2016 | 26 | 0.140 |
Why?
|
| Sepsis | 1 | 2021 | 652 | 0.140 |
Why?
|
| Adult | 6 | 2020 | 77950 | 0.140 |
Why?
|
| Blood Coagulation | 1 | 2016 | 185 | 0.130 |
Why?
|
| Clinical Decision-Making | 1 | 2018 | 524 | 0.130 |
Why?
|
| Clinical Protocols | 1 | 2016 | 467 | 0.120 |
Why?
|
| Transplant Recipients | 1 | 2016 | 324 | 0.120 |
Why?
|
| Monitoring, Physiologic | 1 | 2016 | 502 | 0.110 |
Why?
|
| Retrospective Studies | 5 | 2018 | 37905 | 0.110 |
Why?
|
| Liver Diseases | 1 | 2018 | 574 | 0.110 |
Why?
|
| Male | 6 | 2020 | 123000 | 0.110 |
Why?
|
| Risk Factors | 3 | 2018 | 17523 | 0.100 |
Why?
|
| Middle Aged | 5 | 2019 | 86204 | 0.100 |
Why?
|
| Azabicyclo Compounds | 2 | 2022 | 36 | 0.100 |
Why?
|
| Case-Control Studies | 2 | 2018 | 6100 | 0.100 |
Why?
|
| Female | 6 | 2020 | 141928 | 0.100 |
Why?
|
| Texas | 2 | 2018 | 6311 | 0.090 |
Why?
|
| Incidence | 2 | 2018 | 5673 | 0.090 |
Why?
|
| Aged | 4 | 2018 | 70117 | 0.080 |
Why?
|
| Logistic Models | 1 | 2016 | 3441 | 0.080 |
Why?
|
| Dose-Response Relationship, Drug | 1 | 2016 | 4938 | 0.080 |
Why?
|
| Practice Guidelines as Topic | 1 | 2017 | 2403 | 0.070 |
Why?
|
| HIV Infections | 1 | 2017 | 2134 | 0.060 |
Why?
|
| Young Adult | 2 | 2020 | 21445 | 0.060 |
Why?
|
| Aged, 80 and over | 2 | 2018 | 29902 | 0.050 |
Why?
|
| United States | 1 | 2018 | 15433 | 0.050 |
Why?
|
| Drug Combinations | 1 | 2022 | 621 | 0.050 |
Why?
|
| Pseudomonas aeruginosa | 1 | 2021 | 233 | 0.040 |
Why?
|
| Drug Therapy | 1 | 2018 | 205 | 0.040 |
Why?
|
| Cephalosporins | 1 | 2017 | 148 | 0.040 |
Why?
|
| Phylogeny | 1 | 2017 | 826 | 0.030 |
Why?
|
| Odds Ratio | 1 | 2018 | 2316 | 0.030 |
Why?
|
| Chronic Disease | 1 | 2018 | 1819 | 0.030 |
Why?
|
| Randomized Controlled Trials as Topic | 1 | 2017 | 2594 | 0.020 |
Why?
|
| Prognosis | 1 | 2018 | 21713 | 0.010 |
Why?
|
| Adolescent | 1 | 2018 | 31252 | 0.010 |
Why?
|